PTO shuts down Amgen’s Humira IP challenge

Carly Helfand Amgen has hit a potential snag in its quest to bring a biosimilar of AbbVie cash cow Humira to market. Thursday, the U.S. Patent and Trademark Office declined to review ...

FDA slaps down BioMarin’s Duchenne’s drug as rival nears a moment of truth

John Carroll After outlining its objections to BioMarin's application for its experimental Duchenne muscular dystrophy drug drisapersen in an internal review and hearing clear objections ...

Biden maps out a ‘moonshot’ approach to cancer with plans to ‘break down silos’ in R&D

Damian Garde Vice President Joe Biden fleshed out his plans to take the lead on a global effort to bolster cancer research, hoping to unite industry and academia to push new therapies ...

Single-minded Shire finally pins down Baxalta with $32B deal

Carly Helfand The new year has its first megadeal agreement, thanks to Shire and Baxalta. On Monday, the two finally announced a $ 32 billion tie-up after a months-long pursuit by ...

Pricing pressure: Doubling down on the political drama

John Carroll ​With all the brouhaha over Martin Shkreli's 5000%-plus price hike, it's important to remember what got us to this point on drug pricing and where we're left ...

Brace yourselves: The drug pricing brouhaha isn’t dying down

Tracy Staton Drug prices were already a sore subject, but the pain grew this fall, when the now-former CEO of Turing Pharmaceuticals Martin Shkreli unapologetically jacked up the price ...

Daiichi Sankyo shuts down a German R&D shop

Damian Garde Daiichi Sankyo is closing up its German research outpost, shuttering the former U3 Pharma as it consolidates its global R&D presence. FierceBiotech News

Kite nails down TCR IP in new licensing pact

John Carroll Kite Pharma has moved to cement its control of some of the IP behind its work on T cell receptor-based product candidates that zero in on MAGE A3 and A3/A6 antigens. FierceBiotech ...

UPDATED: Melinta’s CEO steps down amid a big Phase III push

Damian Garde Melinta Therapeutics CEO Mary Szela has left the company in the middle of a late-stage program for its lead antibiotic, a move that comes just months after the biotech ...

Report: Baxalta’s $2B plot to buy Ariad broke down over price

Damian Garde Last week's buzz that Baxalta, angling to shake off some unwanted buyout attention from Shire, had set sights on Ariad Pharmaceuticals sent the latter company's ...

Celgene nails down $7.2B takeover of Receptos

Eric Palmer Celgene Thursday reported that it had completed its $ 7.2 billion buyout of Receptos. Celgene agreed to pay $ 232 per share for the San Diego-headquartered company, a ...

Patrick Soon-Shiong: NantKwest is starting down the path to conquering cancer

John Carroll Patrick Soon-Shiong made several fortunes based on his understanding of cancer and drug development, most recently in today's multibillion-dollar IPO for NantKwest. ...
© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS